Evidence map›Paper›PMID 21714781›Full record

ArticleBiometrics2012

Discussion of the article by Trippa, Rosner, and Müller on Bayesian enrichment strategies for randomized discontinuation trials.

Heinz Schmidli, Beat Neuenschwander

Abstract readComment
PubMed Publisher
In one paragraph

Article in Biometrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Heinz SchmidliStatistical Methodology, Development, Novartis Pharma AG, Basel, Switzerland. heinz.schmidli@novartis.com
Beat Neuenschwander

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We congratulate Trippa, Rosner, and Müller (2011, Biometrics, in press) on an intriguing and timely article. The randomized discontinuation design (RDD) has only recently been used in cancer clinical trials, and methodological understanding on how to best design such studies is limited. The authors’ approach to optimize RDD designs based on prior information and utility considerations is an important step forward. A noteworthy element is their use of a semimechanistic model to describe tumor growth. Mathematical models have provided considerable insight on the complex process of tumor evolution (Preziosi, 2003, Cancer Modelling and Simulation). Utilizing this knowledge should lead to better design, analysis, and decisions.

Indexed as

Bayes TheoremData Interpretation, StatisticalModels, StatisticalBiometryHumansNeoplasmsRandomized Controlled Trials as Topic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.